Home » Stocks » SAGE

Sage Therapeutics, Inc. (SAGE)

Stock Price: $85.00 USD 1.55 (1.86%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 4.96B
Revenue (ttm) 1.11B
Net Income (ttm) 606.07M
Shares Out 51.98M
EPS (ttm) 11.43
PE Ratio 7.44
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $85.00
Previous Close $83.45
Change ($) 1.55
Change (%) 1.86%
Day's Open 81.73
Day's Range 80.47 - 85.10
Day's Volume 1,067,471
52-Week Range 25.01 - 98.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 month ago

American BriVision: Deep Dive Into Market Potential

Other stocks mentioned: ABVC, BIIB, KMDA, MRK, SGEN
Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform t...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform t...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the liv...

The Motley Fool - 2 months ago

Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.

Other stocks mentioned: BLUE, GLPG
Seeking Alpha - 2 months ago

Biogen recently announced a $1.5 billion collaboration agreement with Sage Therapeutics. Despite an earlier failed trial, Zuranolone is a promising therapy for depression.

Other stocks mentioned: BIIB
Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform th...

Schaeffers Research - 2 months ago

The shares of Sage Therapeutics Inc (NASDAQ:SAGE) are down 1.8% at $72.78 at last check, after Raymond James downgraded the stock to "Market Perform" from "Outperform," following its recent $1...

Zacks Investment Research - 2 months ago

Biogen (BIIB) and Sage Therapeutics (SAGE) collaborate to develop latter's zuranolone for depression indications and SAGE-324 for essential tremor.

Other stocks mentioned: BIIB
Market Watch - 3 months ago

Biogen Inc. and Sage Therapeutics Inc. said Monday they have agreed to jointly develop therapies to treat depression and movement disorders in a deal in which Biogen will give Sage $1.525 bill...

Other stocks mentioned: BIIB
Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license ag...

Other stocks mentioned: BIIB
Seeking Alpha - 3 months ago

Sage Therapeutics' (SAGE) Management on Q3 2020 Results - Earnings Call Transcript

Benzinga - 3 months ago

Shares of Sage Therapeutics (NASDAQ: SAGE) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share increased 41.67% year over year to ($2.03), which beat the...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to tran...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform t...

Seeking Alpha - 4 months ago

Sage Therapeutics has shown impressive results on the charts YTD, where shareholders have enjoyed +169% gains since the selloff. The stock has bounced away from support nicely 5 times since th...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to tran...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform t...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform t...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform t...

Zacks Investment Research - 5 months ago

Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

CNBC - 5 months ago

With depression rates up amid the economic and health crises, mental health should be treated like a physical illness, Sage Therapeutics CEO Jeff Jonas said on "Mad Money."

CNBC Television - 5 months ago

Sage Therapeutics CEO: Mental health is integral to returning to work

"We need to treat mental health like a physical illness, treat it urgently, in order to get people back to work and back to their families," Sage Therapeutics CEO Jeff Jonas said.

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc.

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc.

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc.

Seeking Alpha - 6 months ago

Sage Therapeutics, Inc. (SAGE) CEO Jeffrey Jonas on Q2 2020 Results - Earnings Call Transcript

Benzinga - 6 months ago

Shares of Sage Therapeutics (NASDAQ:SAGE) were flat in pre-market trading after the company reported Q2 results.

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc.

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc.

Business Wire - 7 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc.

The Motley Fool - 8 months ago

With its recent clinical trial stumble and falling revenues for its only approved drug on the market, Sage may be in trouble.

Forbes - 8 months ago

If you’re looking to hedge some downside, or if you think the market has gone too far to the upside, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identif...

Other stocks mentioned: ECOR, GRUB, OCGN, RCL
24/7 Wall Street - 8 months ago

The 2020 year is practically halfway done, and this has really been the year of the biotech.

Other stocks mentioned: ACAD, BIIB, BTAI, CRTX, ITCI, NBIX, ZYNE
The Motley Fool - 8 months ago

The company, which failed pivotal clinical trials investigating major depression, aims to reverse its fortunes this year.

Seeking Alpha - 9 months ago

SAGE Therapeutics, Inc. (SAGE) CEO Jeffrey Jonas on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.

Other stocks mentioned: CHE, DXCM, LLY, VRAY
Zacks Investment Research - 10 months ago

As of late, it has definitely been a great time to be an investor in Sage Therapeutics.

Zacks Investment Research - 10 months ago

Sage Therapeutics (SAGE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Market Watch - 10 months ago

Shares of Sage Therapeutics Inc. were down 0.6% in premarket trading on Wednesday after it announced a restructuring plan that includes letting go of 340 employees, which is more than half of ...

Zacks Investment Research - 10 months ago

Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zacks Investment Research - 11 months ago

Sage Therapeutics (SAGE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 11 months ago

Sage Crumbled After Single Trial Failure, But Few Catalysts In The Near Term May Turn Things Around

Seeking Alpha - 1 year ago

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2019 Results Conference Call February 27, 2020 8:00 AM ET

The Motley Fool - 1 year ago

A revenue miss and a lack of news on its depression drug candidate had shareholders down in the dumps.

Zacks Investment Research - 1 year ago

Sage Therapeutics (SAGE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Motley Fool - 1 year ago

An important drug candidate failed to meet its primary endpoint in a clinical trial. That left the door open for a new competitor.

Benzinga - 1 year ago

Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering.

Other stocks mentioned: ALEC, AMGN, FULC, RARE, RDUS, SRPT, VRTX
Benzinga - 1 year ago

Insider buying can be an encouraging signal for potential investors. Two energy companies saw insiders return to add to their stakes last week.

Other stocks mentioned: EPD, PBF
Zacks Investment Research - 1 year ago

Sage Therapeutics (SAGE) shares rose more than 7% in the last trading session, amid huge volumes.

About SAGE

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that i... [Read more...]

Industry
Biotechnology
IPO Date
Jul 18, 2014
CEO
Jeffrey Jonas
Employees
298
Stock Exchange
NASDAQ
Ticker Symbol
SAGE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 22 analysts, the average rating for SAGE stock is "Buy." The 12-month stock price forecast is 102.00, which is an increase of 20.00% from the latest price.

Price Target
$102.00
(20.00% upside)
Analyst Consensus: Buy